RTW Biotech Opportunities NAV falls in 'volatile' period for biotech
RTW Biotech Opportunities Ltd on Thursday said the biotech industry is navigating a ‘complex but increasingly constructive environment’ as it reported a decline in its interim net asset value per share.
RTW Biotech, a London-listed investor focused on high-growth life science assets, reported a NAV per share of $1.70 as of June 30, down 6.1% from $1.81 at December 31.
RTW Biotech reported a minus 6.0% NAV per share return over the period, coming in ahead of the Russell 2000 Biotechnology Index which fell 11.4%, but behind the Nasdaq Biotechnology Index which fell 1.9%.
However, RTW noted that the Russell 2000 Biotechnology Index aligns closer with its investment approach, since it is more heavily tilted toward smaller market cap companies.
Commenting on performance, Chair William Simpson noted that the biotech sector was not ‘immune’ to the volatility experienced by global markets in the first half of the year.
Public investments contributed minus 2.9% to the NAV per share return, said RTW, with Rocket Pharmaceuticals Inc the largest detractor as it contributed minus 4.4%. Of the private investments, Artios served as the largest detractor, contributing minus 3.0% to returns.
Shares in RTW Biotech were 0.5% higher at $1.50 on Thursday morning in London.
‘The first half of 2025 saw one of the most volatile periods for the biotech sector since the company’s launch. Despite the headwinds which led to the NAV falling during the period, the company continues to outperform its reference benchmarks and the wider peer group over the long term,’ said Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments.
‘The biotech industry is navigating a complex but increasingly constructive environment. Policy momentum is leaning pro-innovation, valuations are at multi-year lows, and strategic buyers are stepping in with unprecedented balance sheet firepower. For investors able to look through the short-term noise, the combination of regulatory support, scientific progress, and strategic demand points to a potentially powerful re-rating as we look ahead to the second half and beyond,’ continued Wong.
Copyright 2025 Alliance News Ltd. All Rights Reserved.